XML 36 R26.htm IDEA: XBRL DOCUMENT v3.19.1
Net Income per Share (Tables)
3 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
Basic and Diluted Net Income per Share
The following table presents the calculation of basic and diluted net income per share (in thousands, except per share information):
 
 
Three Months Ended
March 31,
 
2019
 
2018
Net income
$
7,026

 
$
4,928

Basic:
 
 
 
Weighted-average shares of common stock outstanding
31,376

 
32,752

Shares used in computing basic net income per share
31,376

 
32,752

Effect of dilutive securities:
 
 
 
Restricted stock subject to vesting
542

 
491

Shares issuable for acquisition consideration (1)
296

 
547

Shares used in computing diluted net income per share
32,214

 
33,790

 
 
 
 
Basic net income per share
$
0.22

 
$
0.15

Diluted net income per share
$
0.22

 
$
0.15

 
(1)
For the three months ended March 31, 2019, this represents the shares held in escrow pursuant to: (i) the Asset Purchase Agreement with Zeon Solutions Incorporated and certain related entities (collectively, “Zeon”); (ii) the Asset Purchase Agreement with RAS & Associates, LLC (“RAS”); (iii) the Asset Purchase Agreement with Southport Services Group, LLC (“Southport”); (iv) the Asset Purchase Agreement with Stone Temple Consulting Corporation (“Stone Temple”); and (v) the Agreement and Plan of Merger with Elixiter, Inc. (“Elixiter”), as part of the consideration.  For the three months ended March 31, 2018, this represents the shares held in escrow pursuant to: (i) the Asset Purchase Agreement with BioPharm Systems, Inc. (“BioPharm”); (ii) the Asset Purchase Agreement with Zeon; (iii) the Asset Purchase Agreement with RAS; and (iv) the Asset Purchase Agreement with Clarity Consulting, Inc. and Truth Labs, LLC (together, “Clarity”), as part of the consideration.

Antidilutive Securities Excluded from Computation of Earnings Per Share
The number of anti-dilutive securities not included in the calculation of diluted net income per share were as follows (in thousands):
 
Three Months Ended
March 31,
 
2019
 
2018
Restricted stock subject to vesting
105

 
120

Convertible senior notes
3,823

 

Warrants related to the issuance of convertible senior notes
3,823

 

Total anti-dilutive securities
7,751

 
120